Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

PaperCitations, authors & open-access status

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 106 citations, 2023 year and closed oa status.

106
Citations
2023
Year
closed
OA Status

Related on ScholarIQ

Nicolas Mottet
Author
The Lancet Oncology
Journal
Bladder and Urothelial Cancer Treatments
Topic
Bladder and Urothelial Cancer Treatments
Topic
Multiple and Secondary Primary Cancers
Topic
Urinary and Genital Oncology Studies
Topic
470M+ articles · free account